National Cancer Institute; Notice of Closed Meetings, 22051-22053 [2023-07654]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 70 / Wednesday, April 12, 2023 / Notices
milene.brownlow@nih.gov. TTY users
should contact the Federal TTY Relay
Service at 800–877–8339. Requests
should be made at least five business
days in advance of the event.
Additional Health and Safety
Guidance: Before attending a meeting at
an NIH facility, it is important that
visitors review the NIH COVID–19
Safety Plan at https://ors.od.nih.gov/sr/
dohs/safety/NIH-covid-19-safety-plan/
Pages/default.aspx for information
about requirements and procedures for
entering NIH facilities, especially when
the COVID–19 community level is
medium. If the COVID–19 level is high,
the meeting will be held virtually.
In addition, the Safer Federal
Workforce website has FAQs for visitors
at https://
www.saferfederalworkforce.gov/faq/
visitors/. Please note that if an
individual has a COVID–19 diagnosis
within 10 days of the meeting, that
person must attend virtually. (For more
information please read NIH’s
Requirements for Persons after Exposure
at https://ors.od.nih.gov/sr/dohs/safety/
NIH-covid-19-safety-plan/COVIDassessment-testing/Pages/persons-afterexposure.aspx and What Happens When
Someone Tests Positive at https://
ors.od.nih.gov/sr/dohs/safety/NIHcovid-19-safety-plan/COVIDassessment-testing/Pages/testpositive.aspx.) Registration to attend the
meeting virtually will be available
through the end of the meeting at
https://ntp.niehs.nih.gov/go/
iccvamforum-2023. Please continue
checking these websites for the most upto-date guidance as the meeting date
approaches.
Request for Oral Public Statements: In
addition to time for clarifying or followup questions following scheduled
presentations, time will be allotted
during the meeting for oral public
statements with associated slides on
topics relevant to ICCVAM’s mission.
Separate registration for those wishing
to provide public statements is required
and is open through May 9, 2023, at
https://ntp.niehs.nih.gov/go/
iccvamforum-2023. Any meeting
attendee or webcast viewer may ask
clarifying questions during the
appropriate times in the agenda. The
additional registration is only required
for those who wish to give separate
public statements. The number and
length of presentations may be limited
based on available time. Submitters will
be identified by their name and
affiliation and/or sponsoring
organization, if applicable. Participants
registered to present oral public
statements must email their statement to
ICCVAMquestions@niehs.nih.gov by
VerDate Sep<11>2014
19:25 Apr 11, 2023
Jkt 259001
May 12, 2023, to allow time for review
by NICEATM and ICCVAM and posting
to the meeting page prior to the forum.
Persons submitting public statements
and/or associated slides should include
their name, affiliation (if any), mailing
address, telephone, email, and
sponsoring organization (if any) with
the document. Guidelines for public
statements are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Persons presenting oral public
statements will be contacted to arrange
the logistics of their presentations.
Written statements on topics relevant
to ICCVAM’s mission may be submitted
to support an oral public statement or as
standalone documents. These should be
emailed to ICCVAMquestions@
niehs.nih.gov by May 12, 2023. Public
statements received prior to the May 12
deadline will be distributed to
NICEATM and ICCVAM members
before the meeting. Written public
statements received after the deadline
may be reviewed by NICEATM and
ICCVAM at a future date. Materials
submitted to accompany oral public
statements or standalone written
statements should include the
submitters name, affiliation (if any),
mailing address, telephone, email, and
sponsoring organization (if any) with
the document. Guidelines for public
statements are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Responses to this notice are
voluntary. No proprietary, classified,
confidential, or sensitive information
should be included in statements
submitted in response to this notice or
presented during the meeting. This
request for input is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
submitted or for its use of that
information.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 17 federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
22051
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of the National Institute of
Environmental Health Sciences and
provides the authority for ICCVAM
involvement in activities relevant to the
development of alternative test
methods. Additional information about
ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: April 6, 2023.
Richard P. Woychik,
Director, National Institute of Environmental
Health Sciences and National Toxicology
Program, National Institutes of Health.
[FR Doc. 2023–07700 Filed 4–11–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Integrating
Biospecimen Science Approaches.
E:\FR\FM\12APN1.SGM
12APN1
ddrumheller on DSK120RN23PROD with NOTICES1
22052
Federal Register / Vol. 88, No. 70 / Wednesday, April 12, 2023 / Notices
Date: May 11, 2023.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W246, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, Maryland 20850,
240–276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–7: NCI
Clinical and Translational Cancer Research.
Date: May 25, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Rockville,
Maryland 20850, 240–276–7684,
saejeong.kim@nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Transition to
Independence Study Section (I) Transition to
Independence Study Section (I).
Date: June 7–8, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W602, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Delia Tang, M.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W602, Rockville, Maryland 20850,
240–276–6456, tangd@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Assay
Validation of High-Quality Markers for
Clinical Studies in Cancer (UH2/3).
Date: June 8, 2023.
Time: 12:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove. 9609 Medical Center Drive, Room
7W244. Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: John Paul Cairns, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W244,
Rockville, Maryland 20850, 301–461–0303,
paul.cairns@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–6: NCI
Clinical and Translational Cancer Research.
Date: June 13, 2023.
VerDate Sep<11>2014
21:49 Apr 11, 2023
Jkt 259001
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W260, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Robert F. Gahl, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical
Center Drive, Room 7W260, Rockville,
Maryland 20850, 240–276–7869, robert.gahl@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; IMAT
Biospecimen Research.
Date: June 16, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W236, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Shuli Xia, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W236, Rockville, Maryland 20850,
240–276–5256, shuli.xia@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project (P01) SEP–D.
Date: June 20–21, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W244, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Amr M. Ghaleb, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W244,
Rockville, Maryland 20850, 240–276–6611,
amr.ghaleb@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Research Specialist Award (Clinician).
Date: June 20, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W242, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Zhiqiang Zou, M.D., Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W242, Rockville,
Maryland 20850 240–276–6372, zouzhiq@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Building
Collaborative Partnerships and Advancing
Cancer Health Equity.
Date: June 21–22, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
Place: National Cancer Institute Shady
Grove 9609 Medical Center Drive, Room
7W108 Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Rockville, Maryland 20850, 240–276–6343,
schweinfestcw@mail.nih.gov
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–5: NCI
Clinical and Translational Cancer Research.
Date: June 21–22, 2023.
Time: 9:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W240, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Rockville,
Maryland 20850, 240–276–5122,
hasan.siddiqui@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–3: NCI
Clinical and Translational Cancer Research.
Date: June 21–22, 2023.
Time: 9:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W248, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Shree Ram Singh, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W248, Rockville,
Maryland 20850, 240–672–6175, singhshr@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–8: NCI
Clinical and Translational Cancer Research.
Date: June 22, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W106, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Eduardo Emilio Chufan,
Ph.D., Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W106, Rockville, Maryland
20850, 240–276–7975, chufanee@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Pathway to Independence Award for
Outstanding Early-Stage Postdoctoral
Researchers.
Date: June 22–23, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\12APN1.SGM
12APN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 70 / Wednesday, April 12, 2023 / Notices
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Byeong-Chel Lee, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W238 Rockville, Maryland 20850,
240–276–7755, byeong-chel.lee@nih.gov
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI Cancer
Screening Research Network: Clinical
Research Cooperative Agreements (UG1
Clinical Trial Required).
Date: June 27, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W260, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Robert F. Gahl, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical
Center Drive, Room 7W260, Rockville,
Maryland 20850, 240–276–7869, robert.gahl@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI U01
and U24 Review: Precompetitive
Collaboration on Liquid Biopsy for Early
Cancer Assessment.
Date: June 29, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W634, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Michael E. Lindquist,
Ph.D., Scientific Review Officer, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W634, Rockville, Maryland 20850,
mike.lindquist@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2: NCI
Clinical and Translational Cancer Research.
Date: June 29, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W242, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Zhiqiang Zou, M.D., Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W242, Rockville,
Maryland 20850, 240–276–6372, zouzhiq@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
VerDate Sep<11>2014
19:25 Apr 11, 2023
Jkt 259001
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–07654 Filed 4–11–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Gabriella Miller Kids First.
Date: May 5, 2023.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3172, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Barbara J. Thomas, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3172, Bethesda, MD
20892–9306, 301–402–0838,
barbara.thomas@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: April 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–07652 Filed 4–11–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00093
Fmt 4703
22053
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The cooperative agreement
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the cooperative agreement applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; NCATS CTSA UM1 Review
Special Emphasis Panel.
Date: May 11, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Blvd., Room 1080,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Blvd., Room 1080,
Bethesda, MD 20892–4878, (301) 435–0813,
henriquv@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: April 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–07689 Filed 4–11–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
Sfmt 4703
E:\FR\FM\12APN1.SGM
12APN1
Agencies
[Federal Register Volume 88, Number 70 (Wednesday, April 12, 2023)]
[Notices]
[Pages 22051-22053]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07654]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Integrating Biospecimen Science Approaches.
[[Page 22052]]
Date: May 11, 2023.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W246, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Jun Fang, Ph.D., Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W246, Rockville, Maryland 20850, 240-276-5460,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-7: NCI Clinical and Translational Cancer Research.
Date: May 25, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W640, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Saejeong J. Kim, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W640, Rockville, Maryland 20850, 240-276-7684,
[email protected].
Name of Committee: National Cancer Institute Initial Review
Group; Transition to Independence Study Section (I) Transition to
Independence Study Section (I).
Date: June 7-8, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W602, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Delia Tang, M.D., Scientific Review Officer,
Resources and Training Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W602, Rockville, Maryland 20850, 240-276-6456,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Assay Validation of High-Quality Markers for Clinical Studies
in Cancer (UH2/3).
Date: June 8, 2023.
Time: 12:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove. 9609 Medical
Center Drive, Room 7W244. Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: John Paul Cairns, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W244, Rockville, Maryland 20850, 301-461-0303,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-6: NCI Clinical and Translational Cancer Research.
Date: June 13, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W260, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Robert F. Gahl, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical Center Drive, Room
7W260, Rockville, Maryland 20850, 240-276-7869, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; IMAT Biospecimen Research.
Date: June 16, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W236, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Shuli Xia, Ph.D., Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W236, Rockville, Maryland 20850, 240-276-5256,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Program Project (P01) SEP-D.
Date: June 20-21, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W244, Rockville, Maryland 20850, (Telephone
Conference Call).
Contact Person: Amr M. Ghaleb, Ph.D., Scientific Review Officer,
Research Program Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W244, Rockville, Maryland 20850, 240-276-6611, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Research Specialist Award (Clinician).
Date: June 20, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W242, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W242, Rockville, Maryland 20850 240-276-6372, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Building Collaborative Partnerships and Advancing Cancer
Health Equity.
Date: June 21-22, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove 9609 Medical Center
Drive, Room 7W108 Rockville, Maryland 20850 (Virtual Meeting).
Contact Person: Clifford W. Schweinfest, Ph.D., Scientific
Review Officer, Special Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W108, Rockville, Maryland 20850, 240-276-6343,
[email protected]
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-5: NCI Clinical and Translational Cancer Research.
Date: June 21-22, 2023.
Time: 9:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W240, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Hasan Siddiqui, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W240, Rockville, Maryland 20850, 240-276-5122,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-3: NCI Clinical and Translational Cancer Research.
Date: June 21-22, 2023.
Time: 9:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Shree Ram Singh, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W248, Rockville, Maryland 20850, 240-672-6175,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-8: NCI Clinical and Translational Cancer Research.
Date: June 22, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W106, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Eduardo Emilio Chufan, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W106, Rockville, Maryland 20850, 240-276-7975,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Pathway to Independence Award for Outstanding Early-Stage
Postdoctoral Researchers.
Date: June 22-23, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 22053]]
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W238, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Byeong-Chel Lee, Ph.D., Scientific Review
Officer, Resources and Training Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W238 Rockville, Maryland 20850, 240-276-7755,
[email protected]
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Cancer Screening Research Network: Clinical Research
Cooperative Agreements (UG1 Clinical Trial Required).
Date: June 27, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W260, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Robert F. Gahl, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical Center Drive, Room
7W260, Rockville, Maryland 20850, 240-276-7869, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI U01 and U24 Review: Precompetitive Collaboration on
Liquid Biopsy for Early Cancer Assessment.
Date: June 29, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W634, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Michael E. Lindquist, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W634, Rockville, Maryland 20850,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-2: NCI Clinical and Translational Cancer Research.
Date: June 29, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W242, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W242, Rockville, Maryland 20850, 240-276-6372,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-07654 Filed 4-11-23; 8:45 am]
BILLING CODE 4140-01-P